ARAY - Accuray Incorporated
Accuray (NASDAQ: ARAY) stockholders approved three proposals at the company's 2026 Special Meeting of Stockholders, including measures related to a planned preferred-stock financing, an increase in authorized common shares and a potential reverse stock split. The virtual meeting was led by President and Chief Executive Officer Steve La Neve, who said the company chose the format
MADISON, Wis., Oct. 6, 2026 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced that stockholders approved all proposals presented at the company's Special Meeting of Stockholders held on October 6, 2026, enabling Accuray to complete its previously announced transactions with TCW Asset Management Company LLC, the company's primary lender and largest shareholder.
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife PlatformPR NewswireMADISON, Wis., Sept. 27, 2026MADISON, W
MADISON, Wis., Sept. 27, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife® System.
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive CapabilitiesPR Newsw
MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.
BlackRock Inc. bought a new position in Accuray Incorporated (NASDAQ: ARAY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,266,185 shares of the medical equipment provider's stock, valued at approximately $842,000. BlackRock Inc. owned approximately 2.75% of Accuray
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
MADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026.
MADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth.
MADISON, Wis., Aug. 5, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m.
MADISON, Wis., July 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several decisive actions that will drive a significant improvement in its financial position, a fundamental change in its business strategy, the rollout of differentiated technology, and continued transformation in how the company operates.
MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer.
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform.
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
MADISON, Wis., May 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2026.
MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m.
Accuray (NASDAQ: ARAY - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $111.90 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earning overview page for
MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026.
Accuray Incorporated (NASDAQ: ARAY - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 6,598,752 shares, a growth of 20.6% from the February 26th total of 5,471,116 shares. Approximately 5.8% of the shares of the company are sold